Financial reports
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
1 Mar 22
10-Q
2021 Q3
Quarterly report
8 Nov 21
Current reports
8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
28 Feb 24
8-K
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
10 Jan 24
8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
1 Nov 23
8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
1 May 23
8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
28 Feb 23
8-K
U.S. Commercial launch expected Q1 2023
28 Dec 22
8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
10 Nov 22
8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
8 Aug 22
Registration and prospectus
S-3ASR
Automatic shelf registration
2 Sep 22
S-8
Registration of securities for employees
24 Jun 22
424B5
Prospectus supplement for primary offering
16 Dec 20
424B5
Prospectus supplement for primary offering
14 Dec 20
424B5
Prospectus supplement for primary offering
9 Nov 20
424B5
Prospectus supplement for primary offering
18 May 20
424B5
Prospectus supplement for primary offering
14 May 20
424B5
Prospectus supplement for primary offering
20 Mar 20
424B5
Prospectus supplement for primary offering
23 Dec 19
S-3ASR
Automatic shelf registration
5 Sep 19
Proxies
PRE 14A
Preliminary proxy
18 Apr 24
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
21 Apr 23
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
PRE 14A
Preliminary proxy
20 Apr 21
PX14A6G
Letter to shareholders
29 May 20
Other
CT ORDER
Confidential treatment order
18 Sep 18
EFFECT
Notice of effectiveness
24 Jul 18
CORRESP
Correspondence with SEC
18 Jul 18
UPLOAD
Letter from SEC
17 Jul 18
CT ORDER
Confidential treatment order
30 Apr 18
EFFECT
Notice of effectiveness
13 Jun 17
CORRESP
Correspondence with SEC
9 Jun 17
CT ORDER
Confidential treatment order
4 Oct 16
CT ORDER
Confidential treatment order
4 Aug 15
CT ORDER
Confidential treatment order
21 Jan 15
Ownership
4
Sagar Lonial
15 Mar 24
4
Laurence N Charney
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
5
Sean A Power
14 Feb 24
SC 13G/A
Darwin Global Management, Ltd.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
4
Laurence N Charney
8 Jan 24